A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study

Liu, Bin; Qian, Jiayi; Wu, Lingmin; Zeng, Junquan; Xu, Shu-Quan; Yuan, Jin-Hua; Zheng, Yongliang; Xie, Dong; Chen, Xiaolu; Yu, Hongfeng

doi:10.3389/fsurg.2022.987075

Cited by 2 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, old age was not a prognostic risk factor statistically in this study, unlike other studies [ 18 , 19 ]. The reason for this phenomenon might be that the sample size was small, and the cutoff point of age was different.…”

Section: Discussioncontrasting

confidence: 92%

The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study

Jiang

Xie

et al. 2023

J Cardiothorac Surg

Self Cite

View full text Add to dashboard Cite

Purpose This study aimed to investigate the prognostic significance of surgery in large-cell neuroendocrine carcinoma (LCNC) patients. Methods A total of 453 patients from the Surveillance, Epidemiology, and End Results database diagnosed with stage T1-4N0-2M0 LCNC from 2010 to 2015 were analyzed. The propensity-score matching analysis with a ratio of 1:1 was used to minimize the bias effect of other clinical characteristics, and 77 pairs of patients’ data were performed for subsequent statistical analysis. The Cox proportional hazards model, Kaplan-Meier analysis, and Log-rank test were used in the present study. The primary observational endpoint was cancer-specific survival (CSS). Results The 1-year, 3-year, and 5-year CSS rates were 60.0%, 45.0%, and 42.0% in those 453 LCNC patients. Compared with patients who underwent surgical resection, patients without surgery had a lower 5-year CSS rate (18.0% vs. 52.0%, P < 0.001). After analyses of multivariable Cox regression, chemotherapy, T stage, N stage, and surgery were identified as independent prognostic indicators (all P < 0.05). In the cohort of old patients, the median survival time was longer in cases after surgery than those without surgery (13.0 months vs. NA, P < 0.001). Besides, in patients with different clinical characteristics, the receiving surgery was a protective prognostic factor (all hazard ratio < 1, all P < 0.05). In addition, for the cohort with stage T1-2N0-2M0, patients after the operation had more improved outcomes than patients without surgery (P < 0.001). Conclusions We proposed that the surgery could improve the survival outcomes of LCNC patients with stage T1-4N0-2M0. Moreover, old patients could benefit from surgery.

show abstract

Section: Discussioncontrasting

confidence: 92%

The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study

Jiang

Xie

et al. 2023

J Cardiothorac Surg

Self Cite

View full text Add to dashboard Cite

show abstract

“…The OS of NSCLC is only about 20% according to a previous report [4]. The number of factors impacting OS is many, such as treatment approach, age, the level of lactate dehydrogenase, and the time of treatment [5][6][7][8]. Importantly, changes in treatment modalities have profoundly altered the prognostic characteristics of NSCLC patients.…”

Section: Introductionmentioning

confidence: 99%

A Predictive Model for Evaluating Efficacy of Immunotherapy in Non-small-cell Lung Cancer Patients

Zeng

Yuan

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

The predictive accuracy to treatment effect of immune therapy is still poor. Thus, we aimed to develop a predictive model based on gene mutations to assess the immunotherapeutic efficacy in non-small cell lung cancer. Then, 335 NSCLC patients treated with ICIs were included in our study. The least absolute shrinkage and selection operator Cox regression model, multivariable analysis, and Kaplan-Maire test were used in this study. In the end, we constructed a predictive model based on a 42-gene signature. Patients were classified into low-risk and high-risk groups based on risk scores generated from this model. Compared with patients in the high-risk group, patients in the low-risk group had better survival. The results were confirmed in an external validation cohort. Moreover, patients with high TMB and in the high-risk group could not benefit from ICIs. A predictive model of evaluating efficacy of immune therapy was developed and validated. The model is based on multiple genetic information and has clinical translational value.

show abstract

A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study

Cited by 2 publications

References 28 publications

The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study

The survival benefit from surgery on patients with large-cell neuroendocrine carcinoma in the lung: a propensity-score matching study

A Predictive Model for Evaluating Efficacy of Immunotherapy in Non-small-cell Lung Cancer Patients

Contact Info

Product

Resources

About